VSTM vs. VNDA, MACK, XOMA, RIGL, RGLS, LXRX, EBS, OPK, PYXS, and AQST
Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Vanda Pharmaceuticals (VNDA), Merrimack Pharmaceuticals (MACK), XOMA (XOMA), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Emergent BioSolutions (EBS), OPKO Health (OPK), Pyxis Oncology (PYXS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical preparations" industry.
Verastem (NASDAQ:VSTM) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership.
Verastem received 60 more outperform votes than Vanda Pharmaceuticals when rated by MarketBeat users. However, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.20% of users gave Verastem an outperform vote.
Verastem has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Vanda Pharmaceuticals has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
88.4% of Verastem shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 2.2% of Verastem shares are held by company insiders. Comparatively, 7.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Verastem. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 2 mentions for Verastem. Verastem's average media sentiment score of 0.97 beat Vanda Pharmaceuticals' score of 0.63 indicating that Verastem is being referred to more favorably in the media.
Vanda Pharmaceuticals has a net margin of 1.30% compared to Verastem's net margin of 0.00%. Vanda Pharmaceuticals' return on equity of 0.46% beat Verastem's return on equity.
Verastem currently has a consensus price target of $28.79, indicating a potential upside of 164.09%. Given Verastem's higher possible upside, research analysts clearly believe Verastem is more favorable than Vanda Pharmaceuticals.
Summary
Vanda Pharmaceuticals beats Verastem on 11 of the 17 factors compared between the two stocks.
Get Verastem News Delivered to You Automatically
Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verastem Competitors List
Related Companies and Tools
